The pathogenesis of anti-signal recognition particle necrotizing myopathy: A Review.

Immune-mediated necrotizing myopathy (IMNM) is a class of idiopathic inflammatory myopathies. According to the types of antibodies in serum, IMNM can be divided into three subtypes: anti-signal recognition particle (SRP) necrotizing myopathy, 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) necrotizing myopathy, and serum antibody-negative necrotizing myopathy. Different subtypes of IMNM have common characteristics, but the specific pathological mechanisms differ. Anti-SRP necrotizing myopathy is an important type of IMNM. At present, the pathogenesis of the disease is unclear. Most views suggest that the disease is mainly caused by an autoimmune response; therefore, the therapeutic strategy is primarily immune regulation. Recent studies have implicated non-immune mechanisms such as endoplasmic reticulum stress and autophagy in the occurrence and development of the disease. Here, we review what is known about the pathogenesis of anti-SRP necrotizing myopathy and summarize the latest research progress, aiming to better understand the disease and provide new ideas for treatment targets.

• Publication year

  2022

• Venue

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

• Publication date

  2022-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.biopha.2022.113936PMID 36411623
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Selective Autophagy Receptor p62/SQSTM1, a Pivotal Player in Stress and Aging

  2022cited by this paper
• Endoplasmic Reticulum Stress Is Involved in Muscular Pathogenesis in Idiopathic Inflammatory Myopathies

  2022cited by this paper
• miR-18a-3p and Its Target Protein HuR May Regulate Myogenic Differentiation in Immune-Mediated Necrotizing Myopathy

  2022cited by this paper
• Possible future avenues for myositis therapeutics: DM, IMNM and IBM.

  2022cited by this paper
• Endoplasmic reticulum‐stress and unfolded protein response‐activation in immune‐mediated necrotizing myopathy

  2022cited by this paper
• The Genetics of Autoimmune Myositis

  2022cited by this paper
• [A case of anti-SRP antibody-positive immune-mediated necrotizing myopathy triggered by human parvovirus B19 infection].

  2022cited by this paper
• Targeting of Proteins for Translocation at the Endoplasmic Reticulum

  2022cited by this paper
• Autoantibodies in the pathogenesis of idiopathic inflammatory myopathies: Does the endoplasmic reticulum stress response have a role?

  2022cited by this paper
• Therapeutic plasma exchange for the treatment of refractory necrotizing autoimmune myopathy

  2022cited by this paper
• Serum cytokine and chemokine profiles in patients with immune-mediated necrotizing myopathy.

  2022cited by this paper
• Belimumab for Immune-Mediated Necrotizing Myopathy Associated With Anti-SRP Antibodies: A Case Report and Retrospective Review of Patients Treated With Anti-B-Cell Therapy in a Single Center and Literature

  2021cited by this paper
• Idiopathic inflammatory myopathies

  2021cited by this paper
• Immune-mediated necrotizing myopathy (IMNM): A myopathological challenge.

  2021cited by this paper
• Out of Control: The Role of the Ubiquitin Proteasome System in Skeletal Muscle during Inflammation

  2021cited by this paper
• Plasma exchange therapy in refractory inflammatory myopathy with anti-signal recognition particle antibody: a case series.

  2021cited by this paper
• Fusion and beyond: Satellite cell contributions to loading‐induced skeletal muscle adaptation

  2021cited by this paper
• The Efficacy of Tocilizumab in the Treatment of Patients with Refractory Immune-Mediated Necrotizing Myopathies: An Open-Label Pilot Study

  2021cited by this paper
• Complement as a Therapeutic Target in Systemic Autoimmune Diseases

  2021cited by this paper
• QRICH1 dictates the outcome of ER stress through transcriptional control of proteostasis

  2021cited by this paper
• Belimumab for systemic lupus erythematosus.

  2021cited by this paper
• IL-6 in inflammation, autoimmunity and cancer

  2020cited by this paper
• Immune-mediated necrotizing myopathy: clinical features and pathogenesis

  2020cited by this paper
• Factors associated with refractory autoimmune necrotizing myopathy with anti-signal recognition particle antibodies

  2020cited by this paper
• A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors.

  2020cited by this paper
• Isoquercitrin Delays Denervated Soleus Muscle Atrophy by Inhibiting Oxidative Stress and Inflammation

  2020cited by this paper
• Myositis Autoantigen Expression Correlates With Muscle Regeneration but Not Autoantibody Specificity

  2019cited by this paper
• Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy.

  2019cited by this paper
• Autophagy and Energy Metabolism.

  2019cited by this paper
• Genetics of idiopathic inflammatory myopathies: insights into disease pathogenesis

  2019cited by this paper
• Sequestosome‐1 (p62) expression reveals chaperone‐assisted selective autophagy in immune‐mediated necrotizing myopathies

  2019cited by this paper
• Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups

  2019cited by this paper
• Pleiotropy and Specificity: Insights from the Interleukin 6 Family of Cytokines.

  2019cited by this paper
• [Idiopathic inflammatory myopathies].

  2019cited by this paper
• Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients

  2019cited by this paper
• Novel susceptibility alleles in HLA region for myositis and myositis specific autoantibodies in Korean patients.

  2019cited by this paper
• Sequential activation of human signal recognition particle by the ribosome and signal sequence drives efficient protein targeting

  2018cited by this paper
• Risk factors and disease mechanisms in myositis

  2018cited by this paper
• Genome-wide meta-analysis reveals shared new loci in systemic seropositive rheumatic diseases

  2018cited by this paper
• Necrosis in anti-SRP+ and anti-HMGCR+myopathies

  2018cited by this paper
• Serum BAFF in Indian patients with IIM: a retrospective study reveals novel clinico-phenotypic associations in children and adults

  2018cited by this paper
• Signalling for B cell survival.

  2018cited by this paper
• In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy

  2018cited by this paper
• 224th ENMC International Workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016.

  2017cited by this paper
• Crosstalk of autophagy and apoptosis: Involvement of the dual role of autophagy under ER stress

  2017cited by this paper
• Pathogenic role of anti–signal recognition protein and anti–3‐Hydroxy‐3‐methylglutaryl‐CoA reductase antibodies in necrotizing myopathies: Myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies

  2017cited by this paper
• Molecular definitions of autophagy and related processes

  2017cited by this paper
• Spectrum of immune-mediated necrotizing myopathies and their treatments

  2016cited by this paper
• Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy

  2016cited by this paper
• Skeletal muscle wasting and renewal: a pivotal role of myokine IL-6

  2016cited by this paper
• HLA-DRB1 alleles in immune-mediated necrotizing myopathy

  2016cited by this paper
• IL-6 as a keystone cytokine in health and disease

  2015cited by this paper
• Understanding the origin of non-immune cell-mediated weakness in the idiopathic inflammatory myopathies – potential role of ER stress pathways

  2015cited by this paper
• Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients

  2015cited by this paper
• Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies

  2014cited by this paper
• STAT3 signaling controls satellite cell expansion and skeletal muscle repair

  2014cited by this paper
• Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1.

  2014cited by this paper
• Endoplasmic reticulum dysfunction in neurological disease.

  2013cited by this paper
• Complement-mediated muscle cell lysis: a possible mechanism of myonecrosis in anti-SRP associated necrotizing myopathy (ASANM).

  2013cited by this paper
• Endoplasmic reticulum stress sensing in the unfolded protein response.

  2013cited by this paper
• Stat3 activation links a C/EBPδ to myostatin pathway to stimulate loss of muscle mass.

  2013cited by this paper
• Belimumab for systemic lupus erythematosus.

  2013cited by this paper
• BAFF Expression Correlates with Idiopathic Inflammatory Myopathy Disease Activity Measures and Autoantibodies

  2013cited by this paper
• Myopathy associated with antibodies to signal recognition particle: disease progression and neurological outcome.

  2012cited by this paper
• Role of non-immune mechanisms of muscle damage in idiopathic inflammatory myopathies

  2012cited by this paper
• Molecular Mechanism of Co‐translational Protein Targeting by the Signal Recognition Particle

  2011cited by this paper
• Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy.

  2011cited by this paper
• BAFF inhibition: a new class of drugs for the treatment of autoimmunity.

  2011cited by this paper
• Distinct seasonal patterns in the onset of adult idiopathic inflammatory myopathy in patients with anti-Jo-1 and anti-signal recognition particle autoantibodies.

  2010cited by this paper
• Granzyme B cleavage of autoantigens in autoimmunity

  2010cited by this paper
• Shared molecular amino acid signature in the HLA-DR peptide binding pocket predisposes to both autoimmune diabetes and thyroiditis

  2010cited by this paper
• Recognition of a signal peptide by the signal recognition particle

  2010cited by this paper
• Cracking the BAFF code

  2009cited by this paper
• Role of cytokines and chemokines in idiopathic inflammatory myopathies

  2009cited by this paper
• IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting.

  2009cited by this paper
• Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies

  2008cited by this paper
• Nutrient sensing and inflammation in metabolic diseases

  2008cited by this paper
• T cell epitopes of the La/SSB autoantigen in humanized transgenic mice expressing the HLA class II haplotype DRB1*0301/DQB1*0201.

  2007cited by this paper
• IL-13 mediates the recruitment of reserve cells for fusion during IGF-1-induced hypertrophy of human myotubes

  2007cited by this paper
• Skeletal muscle IL-4, IL-4Ralpha, IL-13 and IL-13Ralpha1 expression and response to strength training.

  2007cited by this paper
• Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP).

  2006cited by this paper
• HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies.

  2006cited by this paper
• TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells.

  2006cited by this paper
• Immunogenetic Risk and Protective Factors for the Idiopathic Inflammatory Myopathies: Distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 Allelic Profiles Distinguish European American Patients With Different Myositis Autoantibodies

  2006cited by this paper
• Human autoantibodies against the 54 kDa protein of the signal recognition particle block function at multiple stages

  2006cited by this paper
• Contribution of autoantibodies to the diagnosis and nosology of inflammatory muscle disease.

  2006cited by this paper
• Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy

  2005cited by this paper
• IL-6-induced skeletal muscle atrophy.

  2005cited by this paper
• The BAFF/APRIL system: life beyond B lymphocytes.

  2005cited by this paper
• TNF- acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle

  2005cited by this paper
• 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands.

  2004cited by this paper
• A structural step into the SRP cycle

  2004cited by this paper
• Signal recognition particle Alu domain occupies a defined site at the ribosomal subunit interface upon signal sequence recognition.

  2004cited by this paper
• SRP-mediated protein targeting: structure and function revisited.

  2004cited by this paper
• Structure, function and evolution of the signal recognition particle

  2003cited by this paper
• Role of HuR in Skeletal Myogenesis through Coordinate Regulation of Muscle Differentiation Genes

  2003cited by this paper
• IL-4 acts as a myoblast recruitment factor during mammalian muscle growth.

  2003cited by this paper
• Periodic limb movement syndrome

  2002cited by this paper
• BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells.

  2002cited by this paper
• BAFF-induced NEMO-independent processing of NF-κB2 in maturing B cells

  2002cited by this paper

• Complement-independent pathogenic influences of anti-HMGCR + and anti-SRP + immune-mediated necrotizing myopathy autoantibodies on engineered muscle function

  2025cites this paper
• Risk factors and predictive model for pulmonary arterial hypertension in adult idiopathic-inflammatory-myopathy patients: A cross-sectional study

  2025cites this paper
• The pathogenesis of immune-mediated necrotizing myopathy: Progress and therapeutic implications.

  2025cites this paper
• Successful methotrexate and rituximab combination therapy for a Taiwanese patient with anti-signal recognition particle antibody-positive immune-mediated necrotizing myopathy: A case report.

  2025cites this paper
• Comprehensive Enteroviral Serology Links Infection and Anti‐Melanoma Differentiation‐Associated Protein 5 Dermatomyositis

  2024cites this paper
• The emerging roles of necroptosis in skeletal muscle health and disease

  2024cites this paper
• Immune-mediated necrotizing myopathy: A comprehensive review of the pathogenesis, clinical features, and treatments.

  2024cites this paper
• Distinct pathogenic influence of anti-HMGCR+ and anti-SRP+ immune-mediated necrotizing myopathy autoantibodies on engineered muscle function

  2024cites this paper
• An odd case of immune-mediated necrotizing myopathy, complicated with sagittal, transverse and sigmoid sinus thrombosis

  2023cites this paper